TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00594022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electric stimulation of the Vestibular Nerve - VirtuSom
Description: This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. A small electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electric stim of the Vestibular Nerve - VirtuSom - SHAM
Description: This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. For the Sham Group, NO electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes. This is a sham / placebo device only.
Study: NCT04767724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave
Description: Participants received 3 ESWT sessions once per week for 3 consecutive weeks or a single injection of one mL (40 mg) of betamethasone into the region surrounding the median nerve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave
Description: Participants received 3 ESWT sessions once per week for 3 consecutive weeks or a single injection of one mL (40 mg) of betamethasone into the region surrounding the median nerve.
Study: NCT04627454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discectomy and insertion of dynamic cervical implant in cervical disc herniation
Description: The surgical technique included the use of a conventional anterior cervical approach and discectomy and insertion of dynamic cervical implant after discectomy without fixation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discectomy and insertion of dynamic cervical implant in cervical disc herniation
Description: The surgical technique included the use of a conventional anterior cervical approach and discectomy and insertion of dynamic cervical implant after discectomy without fixation
Study: NCT03180944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.2% Lugol's solution
Description: This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0% Lugol's solution
Description: This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8% Lugol's solution
Description: This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6% Lugol's solution
Description: This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4% Lugol's solution
Description: This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained or less-stained lesions.
Study: NCT02432651

Intervention type: DRUG
Group type: OTHER
Intervention: 6 mg xanthohumol per day
Description: Participants will consume non-alcoholic beverage with 2 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: 12 mg xanthohumol per day
Description: Participants will consume a non-alcoholic beverage with 2 mg xanthohumol at breakfast and lunch and 8 mg at dinner for 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: 24 mg xanthohumol per day
Description: Participants will consume a non-alcoholic beverage with 8 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
Study: NCT02272829

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Choacot: Behavioral Intervention for Chronic Opioid Use
Description: This is an intervention for individuals who use opioid medication for chronic pain, and targets the collaboration between the participant and his/her PCP.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Study: NCT04122547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: Active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet oral od
Study: NCT03169400

Intervention type: DEVICE
Intervention: Theranova dialyzer
Description: Hemoadialysis
Study: NCT00861822

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advanced red blood cell transfusion
Description: Sixty anemic (Hg 100-120 g/L) adult patients undergoing cardiac surgery with CPB will be randomized to the 'advance RBC transfusion' (ART) group or the standard-of-care RBC transfusion' (SRT) group (1:1 ratio).~In the ART group, subjects will receive 1-2 units of stored RBCs 1-2 days before surgery to reach a target Hb of 130-140 g/L. Each unit of blood will be transfused over 2 hours under medical supervision, with appropriate monitoring and management of fluid status to ensure patients are not over-hydrate

Intervention type: OTHER
Group type: OTHER
Intervention: Advanced red blood cell transfusion
Description: Sixty anemic (Hg 100-120 g/L) adult patients undergoing cardiac surgery with CPB will be randomized to the 'advance RBC transfusion' (ART) group or the standard-of-care RBC transfusion' (SRT) group (1:1 ratio).~In the ART group, subjects will receive 1-2 units of stored RBCs 1-2 days before surgery to reach a target Hb of 130-140 g/L. Each unit of blood will be transfused over 2 hours under medical supervision, with appropriate monitoring and management of fluid status to ensure patients are not over-hydrate
Study: NCT00965497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: After confirmation of diagnoses and safety screening escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability. No other psychotropic medications will be permitted during the study. Medications for coexisting medical problems (e.g. hypertension) will be permitted. Study visits will include weekly visits for first 2 weeks and biweekly visits for next 6 weeks. Medications will be dispensed weekly or biweekly and the participants will be followed for 8 weeks.
Study: NCT03688776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1805AA
Description: A moist snuff product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1805AA
Description: A moist snuff product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1805AB
Description: A moist snuff product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1805AB
Description: A moist snuff product
Study: NCT03827447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Oral Capsule
Description: 125 mg capsules every 6 hours for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Gelatin pill manufactured to mimic 125 mg Vancomycin oral capsule
Study: NCT02214953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11634 ER formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11634 ER formulation B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11634 ER formulation M

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11634 ER formulation C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 11634 IR tablet
Study: NCT03127670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanum melongena peel extract 0.05%
Description: Administered topically twice daily for 12 weeks
Study: NCT03701048

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean Section
Description: Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean Section
Description: Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed.
Study: NCT02975076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanchitongshu
Description: The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of Sanchitongshu
Description: The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo of clopidogrel
Study: NCT04515498

Intervention type: DEVICE
Intervention: CloudCath Monitoring System
Description: The CloudCath Monitoring System will analyze effluent dialysate for changes associated with peritonitis.
Study: NCT02838134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: A bolus of 0.7 mg/kg rocuronium is administered just after tracheal intubation and then an infusion of rocuronium (0.3 to 0.4 mg/kg) is started when post-tetanic count (PTC) is more than 0 and titrated towards PTC 1-2.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No additional Rocuronium
Description: No additional rocuronium is administered after tracheal intubation.
Study: NCT01889576

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium Oxide
Study: NCT03981939

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, participants did not receive any intervention in this study and were only observed retrospectively.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, participants did not receive any intervention in this study and were only observed retrospectively.

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study, participants did not receive any intervention in this study and were only observed retrospectively.
Study: NCT01059162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Assisted Non-penetrating glaucoma surgery
Description: A layer by Layer ablation of the deep sclera (under the superficial scleral flap) to achieve functional fluid percolation of the inner eye humor without penetration.
Study: NCT04121780

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Daily self-injections by subjects:~1-year double-blind phase; 6-month open-label extension for those who received placebo during the double-blind phase

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily self-injections by subjects:~1-year double-blind phase
Study: NCT01289210

Intervention type: DRUG
Group type: OTHER
Intervention: VTX-2337 plus radiotherapy
Description: Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.
Study: NCT03728621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normocaloric and balanced diet, physical activity
Description: Promotion of normocaloric \& balanced diet and physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normocaloric and balanced diet, physical activity
Description: Promotion of normocaloric \& balanced diet and physical activity
Study: NCT01815502

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac catheterization
Description: All patients will receive a dobutamine infusion during catheterization. Patients were 1:1 randomized to a single dose of 1 mg/kg of sildenafil (max dose of 20 mg) or placebo 30-90 min prior to beginning of catheterization.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac catheterization
Description: All patients will receive a dobutamine infusion during catheterization. Patients were 1:1 randomized to a single dose of 1 mg/kg of sildenafil (max dose of 20 mg) or placebo 30-90 min prior to beginning of catheterization.
Study: NCT02112877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veniti Vici™ Venous Stent System
Study: NCT01031498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
Study: NCT00004500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant
Description: Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant's body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: The Standard Care (SC) group received therapies including, but not limited to, the use of oxygen, controlled mechanical ventilation (CMV), sedation, paralysis, vasopressors, and/or alkalinization. The use of adjunctive therapies (namely: high frequency oscillatory ventilation, high frequency jet ventilation, bolus surfactant, inhaled nitric oxide, extra-corporeal membrane oxygenation, or systemic corticosteroids) were not included in SC
Study: NCT01963091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
Study: NCT00456781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmentation
Description: Rotator Cuff Repair plus Graft Jacket

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Augmentation
Description: Rotator Cuff Repair plus Graft Jacket

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator Cuff Repair without augmentation
Description: Rotator Cuff Repair without augmentation
Study: NCT03636048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hcl 0.5% Inj
Description: The patients undergo surgery under spinal anesthesia and a catheter would be inserted into epidural space during the procedure. 0.5% bupivacaine is injected into intrathecal space for spinal anesthesia. For pain control, 0.2% ropivacaine is continuously infused into epidural space postoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 10 milligram/ML
Description: The patients undergo surgery under general anesthesia and a catheter would be inserted to abdominal incision site at the end of the operation. Propofol is used for induction of general anesthesia, and sevoflurane is used for maintenance of anesthesia. At the end of the operation, the surgeon inserts wound catheter in the surgical site and connects wound patient-controlled analgesia device filled with 0.5% ropivacaine.
Study: NCT04296669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ergotron LearnFit Sit-Stand desk
Description: An adjustable sit-stand desk design for children

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ergotron LearnFit Sit-Stand desk
Description: An adjustable sit-stand desk design for children
Study: NCT02588092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-301
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-301
Description: Intravenous infusion
Study: NCT01532206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure cuff insufflation
Description: Blood pressure cuff will be inflated to a pressure of 200mmHg for 5 minutes. This will be repeated x 3, separated by 5 minutes.
Study: NCT04178616

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: olfactory testing with specific odorants (localisation and identification)
Description: Olfactory testing : ETOC (European Test of Olfactory capabilities)
Study: NCT01031498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron Group 1: 0.25 mg IV bolus over 30 seconds daily for 5 days, 30 minutes before cytarabine chemotherapy.~Palonosetron Group 2: 0.25 mg IV bolus over 30 seconds on Days 1, 3, and 5 of cytarabine chemotherapy, 30 minutes before chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron Group 1: 0.25 mg IV bolus over 30 seconds daily for 5 days, 30 minutes before cytarabine chemotherapy.~Palonosetron Group 2: 0.25 mg IV bolus over 30 seconds on Days 1, 3, and 5 of cytarabine chemotherapy, 30 minutes before chemotherapy.
Study: NCT00607659

Intervention type: OTHER
Intervention: No intervention, only observational
Description: No intervention, only observational

Intervention type: OTHER
Intervention: No intervention, only observational
Description: No intervention, only observational
Study: NCT03616392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D308, CKD-501
Description: 1. D308~2. CKD-501: Lobeglitazone sulfate 0.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D308, CKD-501
Description: 1. D308~2. CKD-501: Lobeglitazone sulfate 0.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D308, CKD-501
Description: 1. D308~2. CKD-501: Lobeglitazone sulfate 0.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D308, CKD-501
Description: 1. D308~2. CKD-501: Lobeglitazone sulfate 0.5mg
Study: NCT02057432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-operative MRI
Description: Patients will undergo an MRI during surgery.
Study: NCT02020070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Study: NCT01480817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib 400mg po bid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE for HCC with portal vein invasion
Description: The volume of iodized oil ranged from 2 to 12 mL, and the amount of doxorubicin ranged from 10 to 60 mg. Gelatin sponge particles were mixed with mitomycin and contrast material.Cisplatin was infused at the tumor feeder vessels as a solution with a concentration of 0.5 mg/mL at a rate of 5-10 mL/min. The total amount of cisplatin used ranged from 50 to 100 mg depending on the patient's body weight and the level of infusion.
Study: NCT05041777

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. \[2\] In such ways, microscopic details of lesions and tissues can be visualized. This information could be used to identify a lesion as BCC, and further specify the subtype. Therefore, the use of the OCT can reduce the number of biopsies and the accompanying morbidity.

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. \[2\] In such ways, microscopic details of lesions and tissues can be visualized. This information could be used to identify a lesion as BCC, and further specify the subtype. Therefore, the use of the OCT can reduce the number of biopsies and the accompanying morbidity.
Study: NCT03300713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MOCITRAINING program
Description: The program is clinical and psychometric tools for screening for interactions and postpartum psychiatric disorders. The program will expose the existing care arrangements and the different possible orientations of the families according to the identified problem.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: usual follow-up
Description: usual follow-up